Cargando…
Within-class differences in cancer risk for sulfonylurea treatments in patients with type 2 diabetes (ZODIAC-55) – a study protocol
BACKGROUND: Patients with type 2 diabetes (T2D) are at increased risk for developing cancer. As approximately 8% of the world’s population is living with T2D, even a slight increase in cancer risk could result in an enormous impact on the number of persons developing cancer. In addition, several glu...
Autores principales: | Schrijnders, Dennis, de Bock, Geertruida H., Houweling, Sebastiaan T., van Hateren, Kornelis J. J., Groenier, Klaas H., Johnson, Jeffrey A., Bilo, Henk J. G., Kleefstra, Nanne, Landman, Gijs W. D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5482962/ https://www.ncbi.nlm.nih.gov/pubmed/28645260 http://dx.doi.org/10.1186/s12885-017-3433-z |
Ejemplares similares
-
Within-Sulfonylurea-Class Evaluation of Time to Intensification with Insulin (ZODIAC-43)
por: Schrijnders, Dennis, et al.
Publicado: (2016) -
Addition of sulphonylurea to metformin does not relevantly change body weight: a prospective observational cohort study (ZODIAC‐39)
por: Schrijnders, Dennis, et al.
Publicado: (2016) -
Sex Differences in the Quality of Diabetes Care in the Netherlands (ZODIAC-45)
por: Hendriks, Steven H., et al.
Publicado: (2015) -
Metformin Associated With Lower Cancer Mortality in Type 2 Diabetes: ZODIAC-16
por: Landman, Gijs W.D., et al.
Publicado: (2010) -
The Lipid Profile and Mortality Risk in Elderly Type 2 Diabetic Patients: A Ten-Year Follow-Up Study (ZODIAC-13)
por: van Hateren, Kornelis J. J., et al.
Publicado: (2009)